Professional
Added to YB: 2025-01-23
Pitch date: 2025-01-22
CRNX [bullish]
Crinetics Pharmaceuticals, Inc.
+26.79%
current return
Author Info
No bio for this author
Company Info
Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors.
Market Cap
$4.0B
Pitch Price
$38.34
Price Target
55.00 (+13%)
Dividend
N/A
EV/EBITDA
-6.46
P/E
-9.40
EV/Sales
2.0K
Sector
Pharmaceuticals
Category
growth
Jefferies Upgrades Crinetics Pharmaceuticals (CRNX) to Buy; Price Target Raised to $55
CRNX: Jefferies upgrades to Buy, PT $55. Pipeline progress in acromegaly, carcinoid, CAH/Cushing's. $1B LLY takeout option for Radionetics (25% owned). 35-40% pullback overdone. Atumetelan still potential $1B CAH drug. High-quality SMID cap biotech, solid management.
Read full article (1 min)